Actively Recruiting
Evaluation of the ReGelTec HYDRAFIL System for Treating Lumbar Degenerative Disc Disease in Adults with Chronic Low Back Pain
Led by ReGelTec, Inc. · Updated on 2026-09-18
225
Participants Needed
16
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of the ReGelTec HYDRAFIL System in adults with axial chronic low back pain caused by degenerative disc disease DDD. This pivotal, multi-center, randomized controlled trial focuses on patients who continue to experience severe back pain and dysfunction after at least six months of conservative care. The study includes participants aged 22 to 85 years with symptomatic lumbar discs confirmed by imaging and discography. Participants are assigned to one of two groups the treatment arm receives the ReGelTec HYDRAFIL System hydrogel spinal implant combined with continued non-surgical conservative care, while the control arm receives conservative care plus a sham procedure involving needle advancement without muscle contact. After 24 months, eligible control participants may crossover to receive the treatment. The study monitors outcomes over at least 12 months and includes follow-up assessments. During the trial, participants undergo various evaluations including imaging MRI, discography, clinical assessments, and symptom monitoring. Researchers measure clinical success through a composite endpoint at 12 months. Participants are expected to adhere to follow-up schedules and complete questionnaires. Safety and effectiveness are continuously assessed throughout the study period, which extends up to the study completion date in late 2028.
CONDITIONS
Brief Title
HYDRAFIL-D: HYDRogel Augmentation For Intervertebral Lumbar Discs
Research Team
S
Seth Kaufman
E
Elisa B Storyk, MPH, CCRP
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here